🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against superbug strains of the pathogen, according to researchers.

A Global Challenge

Cases of gonorrhoea are increasing worldwide, with data suggesting more than 82 million new cases per year. Especially elevated rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the face of rising global incidence, the spread of superbugs and the highly restricted available drugs currently available.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the American regulatory agency in recent days for treating gonorrhoea. This infection can lead to major issues, including infertility. Researchers hope that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, also received approval in close succession. This medication, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the drug firm Innoviva to see it through.

“This milestone signifies a huge turning point in the management of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

As per findings detailed in a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which uses two antibiotics. The trial involved nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the ability to register and commercialise the drug in numerous developing nations.

Doctors directly involved have expressed optimism. The availability of a one-pill regimen like this is seen as a "critical tool" for public health efforts. This is deemed essential to alleviate the strain of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.